Wednesday 28 July 2021
Home      All news      Contact us      RSS      English
Thaipr - 7 days ago

RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib

Patient follow-up completed for the 475-patient global Phase 2/3 study of oral opaganib for severe COVID-19 Top-line results expected in the coming weeks Opaganib, a novel, dual antiviral and anti-inflammatory investigational COVID-19 pill, demonstrated potent inhibition of Beta and Gamma variants and is expected to be effective against emerging variants, including Delta and Delta Plus RedHill [ ] The post RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib appeared first on ThaiPR.NET.


Latest News
Hashtags:   

RedHill

 | 

Biopharma

 | 

Announces

 | 

Patient

 | 

Phase

 | 

COVID

 | 

Study

 | 

Opaganib

 | 

Sources